Leading PET Imaging Expert Returns to Yale Psychiatry Faculty
11/28/2011: Brain scan expert Marc Laruelle, MD will re-join Yale Psychiatry Faculty, heading the Department's Division of Neuroimaging Research as well as the Laboratory of Molecular Neuroimaging in the Clinical Neuroscience Division of the VA National Center for PTSD.
"We are thrilled that Dr. Laruelle is returning to Yale," said Matthew State, MD, PhD, the Department's Deputy Chair for Research. "He’s a world leader in molecular imaging who has a wealth of experience in academia as well as industry. It’s very exciting to have him back. There is no question he will further energize translational neuroscience research in the Department in a whole host of areas, including schizophrenia and substance abuse"
Dr. Laruelle received his medical degree from the Université Catholique de Louvain, Brussels, Belgium in 1982. After completing the Belgian Neuropsychiatry Residency Program in 1988, he went on to a fellowship at the Clinical Brain Disorder Branch of NIMH in Washington DC.
Between 1991 and 1996, he served as Assistant Professor in Yale's Department of Psychiatry, working within the neuroimaging research group let by Dr. Robert Innis. At Yale, Dr. Laruelle led a multidisciplinary project that used SPECT imaging to provide the first direct evidence of dopamine system hyperactivity in schizophrenia, a long-standing hypothesis in the field of schizophrenia research. In 1996, he became an Associate Professor of Psychiatry and Radiology at Columbia, where he directed the Division of Functional Brain Mapping. In 2005, he was promoted to Professor of Psychiatry and Radiology at Columbia University and became Director of the University's Conte Center for the study of Schizophrenia.
Most recently, Dr. Laruelle served as Vice President of the Discovery Performance Unit (DPU) for Schizophrenia and Cognitive Disorders at the GlaxoSmithKline (GSK) Neurosciences Center of Excellence for Drug Discovery. DPU was tasked with discovering, developing and delivering novel medications for the treatment of Schizophrenia, Alzheimer's, and other cognitive disorders.
Throughout his tenure at GSK, Dr. Laruelle continued his clinical research on brain imaging and CNS drug development as an Adjunct Professor at Columbia University and Professor at London's Imperial College.
Dr. Laruelle has authored or coauthored more than 200 papers and book chapters on brain imaging and schizophrenia pathophysiology. He is the recipient of the 1996 Paul Janssen Award for Schizophrenia Research from the International College of Neuro-Psychopharmacology (CINP) and the 2004 International Joel Elkes Award from the American College of Neuropsychopharmacology (ACNP).